XPhyto Provides Update on Parkinsons' Transdermal Patch
Vancouver, British Columbia--(Newsfile Corp. - August 25, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) ("XPhyto" or the "Company"), a next generation bioscience company, is pleased to announce an update on its transdermal delivery system ("TDS") for the neurologic drug Rotigotine. Further to the Company's press release dated, June 8, 2020, regarding formula finalization, Vektor Pharma TF GmbH ("Vektor"), a wholly owned German subsidiary of XPhyto, has now completed...
2020-08-25 3:05 AM EDT
XPhyto Therapeutics Corp.: COVID-19 Rapid Screening Test Prototype Validation
Vancouver, British Columbia--(Newsfile Corp. - July 6, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) (OTC Pink: XPHYF) ("XPhyto" or the "Company") is pleased to announce that its exclusive diagnostic partner, 3a-Diagnostics GmbH ("3a"), has confirmed successful function of its novel and proprietary COVID-19 (SARS-CoV-2) RNA probes and its universal coronavirus RNA probes in prototype lateral flow assay (the "LFA") testing. Visual confirmation of test results (probe activation) was...
2020-07-06 3:05 AM EDT
XPhyto Engages Knox Communications Inc. for Investor Relations Services
Vancouver, British Columbia--(Newsfile Corp. - July 1, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) (OTC PINK: XPHYF) ("XPhyto" or the "Company") is pleased to announce that it has entered into an investor relations consulting agreement (the "Agreement") with Knox Communications Inc. ("KCI") to carryout marketing and investor communication activities for the Company. KCI's founder and principal, Knox Henderson, brings more than 25 years' experience in investor relations, corporate...
2020-07-01 1:31 AM EDT
XPhyto Therapeutics Corp.: Infectious Disease Oral Screening Test Advancement
Vancouver, British Columbia--(Newsfile Corp. - June 15, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) (OTC Pink: XPHYF) ("XPhyto" or the "Company") is pleased to announce that its wholly owned German subsidiary, Vektor Pharma TF GmbH ("Vektor"), has successfully incorporated peptide biosensors into its oral dissolvable thin film ("ODF") platform. XPhyto and its diagnostic partner, 3a-Diagnostics GmbH ("3a"), are developing pathogen-specific ODF biosensors for infectious diseases,...
2020-06-15 3:30 AM EDT
XPhyto's Diagnostic Partners Receive BMBF Grant for Infectious Disease Screening Tests
Vancouver, British Columbia--(Newsfile Corp. - June 10, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) (OTC Pink: XPHYF) ("XPhyto" or the "Company") is pleased to announce that its diagnostic partner, 3a-Diagnostics GmbH ("3a") and their contract research collaborators, have received a €254,200 grant from the German Federal Ministry of Education and Research ("BMBF"). The BMBF grant is part of the "KMU-innovativ" program for small and medium-sized enterprises that are pioneering...
2020-06-10 3:30 AM EDT
RETRANSMISSION: COVID-19 Test and Development Programs Update
Vancouver, British Columbia--(Newsfile Corp. - March 23, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) (OTC PINK: XPHYF) ("XPhyto" or the "Company") is pleased to announce updates to its infectious disease programs, particularly as they relate to the COVID-19 (SARS-CoV-2) pandemic.XPhyto's wholly owned German subsidiary, Vektor Pharma TF GmbH ("Vektor"), has entered into a binding standstill agreement with a European biotechnology company for development of a low-cost rapid...
2020-03-23 3:02 AM EDT
XPhyto Announces COVID-19 Test and Development Programs Update
Vancouver, British Columbia--(Newsfile Corp. - March 20, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) (OTC Pink: XPHYF) ("XPhyto" or the "Company") is pleased to announce updates to its infectious disease programs, particularly as they relate to the COVID-19 (SARS-CoV-2) pandemic.XPhyto's wholly owned German subsidiary, Vektor Pharma TF GmbH ("Vektor"), has entered into a binding standstill agreement with a European biotechnology company for development of a low-cost rapid...
2020-03-20 4:15 PM EDT
XPhyto Therapeutics Epilepsy Treatment Program
Vancouver, British Columbia--(Newsfile Corp. - March 19, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) (OTC: XPHYF) ("XPhyto" or the "Company") is pleased to announce significant progress with respect to development of its cannabidiol ("CBD") based Epilepsy product. Further to the Company's press release dated December 9, 2019, titled "Epilepsy Treatment to be Developed with XPhyto Therapeutics Thin Film Delivery System," and based on recent positive product development results,...
2020-03-19 12:45 PM EDT
XPhyto Therapeutics Initiates Infectious Disease Programs
Vancouver, British Columbia--(Newsfile Corp. - March 3, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) ("XPhyto" or the "Company") is pleased to announce that its wholly owned German subsidiary, Vektor Pharma TF GmbH ("Vektor"), will be commencing several research and development programs related to infectious disease. These programs include in-vitro study of thin film delivery of cannabigerol (CBG) and quercetin for potential anti-bacterial and anti-viral treatments, respectively,...
2020-03-03 3:05 AM EST
Exclusive Strategic Partnership Commenced Between XPhyto Therapeutics and Elite Bavarian Brewing & Beverage Institute Weihenstephan
Vancouver, British Columbia--(Newsfile Corp. - February 18, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE:4XT) ("XPhyto" or the "Company") is pleased to announce that its wholly owned German subsidiary, Bunker Pflanzenextrakte GmbH ("Bunker"), has begun its strategic exclusive partnership for research and development of cannabis focused products, specifically beverages, with the chair of brewing and beverage technology at the Technical University of Munich ("TUM"), School of Life...
2020-02-18 3:05 AM EST
XPhyto Therapeutics Announces Strategic Supply, Import and Distribution Agreement for the German Cannabis Market
Vancouver, British Columbia--(Newsfile Corp. - January 27, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) ("XPhyto" or the "Company") is pleased to announce that the Company has signed a three year definitive supply, import and distribution agreement (the "Agreement") with PharmaCielo Ltd. ("PharmaCielo"), one of the largest, highest quality, and lowest cost cannabis cultivators in the world.PharmaCielo (TSXV: PCLO) (OTCQX: PCLOF) is a global company, headquartered in Canada, with a...
2020-01-27 7:30 AM EST
Epilepsy Treatment to Be Developed with XPhyto Therapeutics' Oral Thin Film Delivery System
Vancouver, British Columbia--(Newsfile Corp. - December 9, 2019) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) ("XPhyto" or the "Company") is pleased to announce that the development of Epilepsy treatment products using its proprietary oral thin film delivery system will be a priority initiative for 2020. The Company is focusing on generic cannabidiol-based dissolvable ora
2019-12-09 3:05 AM EST
XPhyto Therapeutics Developing Epilepsy Treatment with Oral Thin Film Delivery System
Vancouver, British Columbia--(Newsfile Corp. - December 6, 2019) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) ("XPhyto" or the "Company") is pleased to announce that the development of Epilepsy treatment products using its proprietary oral thin film delivery system will be a priority initiative for 2020. The Company is focusing on generic cannabidiol-based dissolvable oral wafers for the treatment of severe childhood forms of Epilepsy, specifically Dravet syndrome ("Dravet") and...
2019-12-06 4:05 PM EST
XPhyto Therapeutics Pharmaceutical-Grade Cannabis Extraction Lab
Vancouver, British Columbia--(Newsfile Corp. - November 25, 2019) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE:4XT) ("XPhyto" or the "Company") is pleased to announce that the Company's pharmaceutical grade extraction and processing laboratory (the "Lab") at the Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta (the "Faculty of Pharmacy"), is now complete and is ready for commissioning and operations.The XPhyto team at the Faculty of Pharmacy recently...
2019-11-25 1:14 PM EST
Xphyto Therapeutics Oral and Transdermal Cannabis Delivery and Dosage Systems
Vancouver, British Columbia--(Newsfile Corp. - November 12, 2019) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) ("XPhyto" or the "Company") is pleased to provide an update on the Company's thin film cannabis delivery and dosage systems in development by XPhyto's wholly owned German subsidiary, Vektor Pharma TF GmbH ("Vektor"). Vektor is a narcotics manufacturer, importer, and researcher located near Munich, Germany.For over a decade, Vektor's founder and managing director, Professor...
2019-11-12 9:00 AM EST
XPhyto Therapeutics Signs Term Sheet for German Cannabis Distribution
Vancouver, British Columbia--(Newsfile Corp. - November 4, 2019) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) ("XPhyto" or the "Company") is pleased to announce that it has signed a term sheet (the "Term Sheet") with a major cannabis grower and processor (the "Supplier") for exclusive distribution of EU GMP flower, extracts, isolates, and crystallites in Germany. The supplier is a major international grower and extractor in the process of EU GMP certification of its facilities and with...
2019-11-04 3:33 PM EST
XPhyto Therapeutics Engages Global Cannabis Expert for German Operations
Vancouver, British Columbia--(Newsfile Corp. - September 19, 2019) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) ("XPhyto" or the "Company") is pleased to announce that it has entered into an exclusive two year European consulting agreement (the "Agreement") with Stephen Schroeder, a leading international cannabis expert (the "Consultant"). The Consultant's initial mandate is the design, renovation, and commissioning of XPhyto's state-of-the-art hydroponics and extraction facility, the...
2019-09-19 3:05 AM EDT
XPhyto Therapeutics Signs Exclusive German Cannabis Agreement with Elite Bavarian Brewing & Beverage Institute
Vancouver, British Columbia--(Newsfile Corp. - September 9, 2019) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) ("XPhyto" or the "Company") is pleased to announce that its wholly owned German subsidiary, Bunker Pflanzenextrakte GmbH ("Bunker"), has entered into an exclusive cannabis research and development agreement (the "Agreement") with the chair of brewing and beverage technology at the Technical University of Munich ("TUM"), School of Life Sciences Weihenstephan...
2019-09-09 3:01 AM EDT
XPhyto Therapeutics to Acquire German Narcotics Company
Vancouver, British Columbia--(Newsfile Corp. - August 26, 2019) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) ("XPhyto" or the "Company") is pleased to announce that it has entered into a definitive share purchase agreement (the "Agreement") with Vektor Pharma TF GmbH ("Vektor"), a German narcotics manufacturer, to acquire 100% of the issued and outstanding shares. XPhyto has also entered into an equipment purchase agreement (the "Equipment Agreement") with an affiliated company to...
2019-08-26 1:29 PM EDT
XPhyto Therapeutics Enters Exclusive Cannabis Research and Development Agreement with the Technical University of Munich
Vancouver, British Columbia--(Newsfile Corp. - August 14, 2019) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) ("XPhyto" or the "Company") is pleased to announce that its wholly owned German subsidiary, Bunker Pflanzenextrakte GmbH ("Bunker"), has entered into an exclusive cannabis research and development agreement (the "R&D Agreement") with the department of biochemistry at the Technical University of Munich ("TUM").Pursuant to the R&D Agreement, initial research will focus on the...
2019-08-14 9:00 AM EDT